A novel combination (“CHAP”) regimen for management of livedoid vasculopathy in 12 patients

Published: 16 June 2022| Version 1 | DOI: 10.17632/6vp4h5yzck.1
Contributor:
Alexandra Coromilas

Description

Figure 1. Representative before (A) and after (B) images of patient 11 three months after initiation of the "CHAP" regimen (and discontinuation of prednisone and sulfasalazine), showing resolution of painful ulcerations and jagged purpuric macules without formation of new lesions.

Files

Institutions

University of Pennsylvania

Categories

Dermatology

Licence